Navigation Links
Impliant Granted Two New U.S. Patents and Successfully Defends European Patent Opposition Case
Date:6/9/2009

PRINCETON, N.J., June 9 /PRNewswire/ -- Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that the European Patent Office has confirmed the validity of one of its key patents following an Opposition by Archus Orthopedics, Inc. (Redmond, WA) that concluded with oral proceedings on May 12, 2009 in Munich, Germany. This patent (EP1578314 B1), originally issued to Impliant on May 30, 2007, involves among others the company's flagship product, the TOPS System, a Total Posterior Arthroplasty device designed to treat lumbar spinal stenosis with or without facet arthrosis and spondylolisthesis. Archus challenged the patent on the grounds of being too broad, but the European Patent Office rejected the opposition and upheld every claim of the patent.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080527/NETU060LOGO )

Impliant also announced that it has been granted two additional patents in the United States. The first (US 7537613), granted on May 26, 2009, is another patent that directs to the company's TOPS System. The second (US 20050197705), already a patent in Europe (EP1646338), entails a unique translateral spinal disc replacement.

"We are very pleased by the outcome of these procedings," said Todd Potokar, President and CEO of Impliant. "The successful defense of one of our main patents in Europe coupled with the addition of two new patents in the U.S. further strengthens our robust IP portfolio."

Impliant is applying cutting-edge materials and crossbar biomechanical techniques to develop a new class of spine arthroplasty devices that target over 40% of the patients worldwide who undergo fusion surgery and could benefit from a Total Posterior Arthroplasty solution.

About the TOPS(TM) System

Impliant's TOPS(TM) System, a mobile posterior device, is designed to stabilize but not fuse the L3-4 or L4-5 vertebral level to alleviate pain stemming from spinal stenosis with or without degenerative facet arthrosis, and spondylolisthesis. Following a laminectomy and medial facetectomy, the device is affixed to the spine via four pedicle screws using a standard posterior surgical approach. Impliant believes that the TOPS(TM) System could benefit over 500,000 patients worldwide undergoing spinal fusion surgery each year. The TOPS(TM) System is not approved for sale in the United States.

About Impliant, Inc.

Impliant, Inc. is a privately held company engaged in the development of novel spine arthroplasty solutions for some of the most prevalent pathologies of the spine. The company is currently developing the TOPS(TM) System, which has the longest clinical history in the Total Posterior Arthroplasty market segment, dating to January 2005. Impliant is also developing several next-generation and multi-level technologies to further increase its addressable market. Impliant is headquartered in Princeton, NJ with research facilities located in Ramat Poleg, Israel. Shareholders include Elron Electronic Industries Ltd. (Nasdaq & TASE: ELRN). For more information about Impliant, please visit www.impliant.com.


'/>"/>
SOURCE Impliant, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System
2. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
3. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
4. USC granted $8.4 million for autism research
5. Aida Granted Additional Anti-Cancer Patent
6. CME LLC Granted Five-Year Full Approval by the American Psychological Association
7. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
8. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
9. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
10. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
11. Phylonix granted broad European patent for transplanting human cells into zebrafish
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Georgia (PRWEB) , ... May 26, 2016 , ... ... certificate in intellectual property (IP) to its specialty academic programs. , Answering to ... the college’s existing certificate programs in health law, and environmental and land use ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox ... new model of care for living and healing, celebrated its grand opening, today. The ... a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling time ...
(Date:5/26/2016)... ... 2016 , ... MadgeTech will be showcasing its line of data logging ... at the MadgeTech headquarters. With products sold in more than 100 countries around the ... NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... An April ... American families. , The 550 employees of Sun Health Senior Living (SHSL) ... Aetna that reduces their doctor and prescription copays for the year, while holding the ...
(Date:5/26/2016)... ... 2016 , ... Leadership of Life Science Logistics (LSL), a ... earned its ISO 13485 certification, indicating the company’s quality control system for medical ... associated with ISO quality standard 13485. , BSI Group America, Inc., a ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
(Date:5/24/2016)... 2016   ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der ... ‚ausgezeichneter plus guter , Reinigung ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... Daten von der MORA-Studie der Phase III für ...
(Date:5/24/2016)... -- ARANZ Medical  Ltd a specialist in ... been named the Coretex Hi-Tech Emerging Company of the Year ... Bruce Davey , CEO of ARANZ Medical says, "This ... to be recognised for the work we are doing to ... 35 countries around the world from Sub-Saharan Africa through to ...
Breaking Medicine Technology: